Lisdexamfetamine dimesylate (Tyvense®) for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.
Rapid Review
Commenced | Completed | Outcome |
09/02/2013 | 28/02/2013 | Full Pharmacoeconomic Assessment Not Recommended |